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Experimental Identification of Chemical
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by Umberto Saffiotti*
Experimental methods for the identification of chemical carcinogens have been extensively developed,
including animal bioassay methods, animal models for cancer induction at major organ sites, models for
the study ofthe effectsofcarcinogens in cells and tissues in culture and methods for the study ofmolecular
events (metabolic activation, binding and detoxification of carcinogens; DNA damage and repair;
mutagenicity). Current sources of documentation on carcinogenicity data are reviewed. The number of
"known carcinogens" will vary considerably, depending on the criteria adopted for accepting evidence of
carcinogenicity.
Criteria for the evaluation of risks, benefits, and technological alternatives for public policy on en-
vironmental carcinogens are reviewed and the following steps discussed: registration of environmental
chemical carcinogens and their uses; risk evaluation (considering sources, adequacy, quality and limits of
the evidence; quantitative dose-response extrapolation within the same biological system; and species and
model conversion factors); benefits evaluation; analysis oftechnological alternatives; comparativejudgment
and decision; open public documentation.
The problem of animal-to-human correlations is considered, particularly for respiratory car-
cinogenesis. A laboratory approach is reviewed which includes: development and study of whole animal
models forcarcinogenesis, analysis ofanimal tissue responses to carcinogens in vivo and through in vitro
culture methods for morphological and biochemical studies, and development ofin vitro culture methods
for human target tissues. This approach is aimed at providing an experimentally controlled and quantifi-




Methods for identifying the carcinogenicity of
chemicals are based on different levels of observa-
tion: human epidemiology and pathology, whole
animal studies, in vitro cellular studies, and
mutagenesis and molecular interaction studies.
Human and/or whole animal evidence, when ade-
quately substantiated, is the presently established
basis for classifying a chemical as a carcinogen.
Evidence based on cellular transformation,
mutagenesis, chemical structure and chemical reac-
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tivity is now providing suggestive or supportive
data, but the predictiveness ofthese methods is still
in the process of being validated (1, 2).
Epidemiologic evidence, even with its limita-
tions, has pointed to clear trends which indicate the
major role of environmental agents in the causation
of human cancer (3-5).
Experimentation in animal models allowed us to
observe a close similarity between the development
of cancers in the laboratory animals and in their
human counterpart. The development of animal
models for carcinogenesis represents a major
methodological step in the investigation of the ef-
fects of carcinogens on their target tissues, as well
as a powerful tool in defining their metabolic path-
ways and the permissive host conditions required
for a carcinogenic response (2).
Most of the major types of human cancers have
been reproduced in animal models by chemical in-
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semble those known from human pathology. This
close correlation by itself strongly supports the evi-
dence for a chemical origin of a large proportion of
human cancers (6).
Great progress was made in the last decade in the
development of models for the study of neoplastic
transformation induced by chemical and physical
agents in cells in culture. These methods are now
undergoing evaluation to determine their repro-
ducibility and reliability for use both in car-
cinogenesis research and for bioassays. The de-
velopment, definition and validation of short-term
screening methods for carcinogenesis were recently
reviewed at a conference organized by the IARC in
Brussels in June, 1975 (7), and at a Seminar and
Workshop held at the Given Institute of Pathobiol-
ogy in Aspen, Colorado, in July, 1976 (8).
Molecular events in carcinogenesis have also
been studied, including those that lead to a critical
DNA damage and can be expressed as mutations and
those affecting the metabolic activation and detoxifi-
cation of carcinogens, their interaction and binding
with target macromolecules, the damage and repair
ofDNA as well as the effects on cell regulatory con-
trol mechanisms.
There is a great need now to correlate the effect
of carcinogens through all levels of observation,
from the human and the whole animal level to the
tissue and cellular level and to the molecular level.
For the purpose of defining chemicals as car-
cinogens, itis important to consider both the quality
of the evidence and its extent (2).
Bioassay procedures, initially outlined by several
expert committees (9-14) were subsequently further
developed and specified in much greater detail by
the NCI Carcinogenesis Program as guidelines for
carcinogen bioassays (15). A model for the fully
detailed publication ofthe reports ofsuch bioassays
was also established (16).
Documentation of chemical carcinogenicity data
is provided by the following sources: (I) IARC
Monographs on the Evaluation of Carcinogenic
Risk of Chemicals to Man, published by the Inter-
national Agency for Research on Cancer (17) which
are, at present, the only extensive reference source
of carcinogenicity data evaluated by a systematic
process ofcritical review ofthe experimental condi-
tions, bioassay protocols, standards of pathology
and results; (2) Survey ofCompounds Which Have
Been Tested for Carcinogenic Activity," published
by the National Cancer Institute (18) which consti-
tutes a key documentation source, but without criti-
cal evaluation of the literature data; (3) Suspected
Carcinogens, a Subtlle of the NIOSH Toxic Sub-
stance List, published by the National Institute for
Occupational Safety and Health (19) which lists
about 1500 chemicals reported in the literature as
having "neoplastic" or "carcinogenic'" effects,
with no critical evaluation; (4) other lists of car-
cinogens compiled by various individual authors or
groups in several books on carcinogenesis.
I believe that it is very important that all these
sources be used with great caution, particularly
when they have not been assembled through a criti-
cal review process.
The number of "known carcinogens" will vary
considerably, depending on the degree of critical
stringency adopted for accepting evidence of car-
cinogenicity (2).
Criteria were recently proposed (6) for the clas-
sification of the evidence ofcarcinogenicity into the
following three categories: positive, negative under
the conditions of observation, and inconclusive.
Evaluation of Risks, Benefits and
Technological Alternatives for
Public Policies on Environmental
Carcinogenesis
In the implementation of public health policies, a
society has to make operational choices and deci-
sions. Implicit in them is ajudgment on the balance
ofbenefits and risks; in addition, I believe that par-
ticular attention should be given to a choice oftech-
nological alternatives. These evaluations are dif-
ficult and usually based on "soft" evidence: errors
injudgment can lead to major human suffering and
loss. If we accept, as a society, that cancer preven-
tion is both feasible and needed, then we should
commit ourselves to the side of prudence in our
judgment and make sure that we avoid under-
estimating the risk and that we avoid overestimating
the benefits. A special policy decision is required
when the evidence for the carcinogenicity of an
agent is inconclusive. The most "prudent" policy is
to consider all agents, for which the evidence is not
clearly negative under accepted minimum condi-
tions of observation, as if they were positive: this
policy may not always be applicable under practical
conditions, but when applicable it will ensure max-
imum protection. In other words, for a prudent tox-
icological policy a chemical should be considered
guilty until proven innocent (20). The least prudent
policy is to consider all chemicals which have not
been conclusively proven positive as if they were
negative, including those for which various levels of
suspicion may exist and may eventually be con-
firmed by subsequent more adequate observa-
tions. These opposite attitudes are reflected in the
Environmental Health Perspectivesapproaches to legislation and regulation of car-
cinogens in different countries and for different
types of exposure.
The analysis of risks and the analysis ofbenefits
are two separate endeavors, based on different
principles, using different methods and concerning
different disciplines. A lot of confusion and con-
troversies have arisen from the interferences ofone
ofthese evaluations into the domain ofthe other. It
is essential that the integrity and objectivity ofthese
analyses be ensured and that no pressure be exerted
on their scientific independence and impartiality.
The evaluation of the balance of benefits and
risks for public policy requires, in my view, the
following necessary and separate steps.
Registration of Environmental Chemical
Carcinogens and Their Uses
We know very little, as individuals, of what hits
us in our everyday life. The available information
basis is still scanty. The Carcinogenesis Program of
the National Cancer Institute, through support of a
collaborative research project at the Stanford Re-
search Institute, has endeavored to obtain data on
the environmental distribution and human exposure
levels oflarge numbers ofenvironmental chemicals,
and has contributed this information to the IARC
Monographs (17). In the United States, the Toxic
Substances Control Act of 1976 contains a provi-
sion for notification to the Government of new
chemicals and new major uses of chemicals. This
will provide a much needed basis of knowledge on
the nature and extent of chemical exposures in our
environment. More specifically, in order to assess
the population risk from chemical carcinogens, I
believe that it would be extremely useful to estab-
lish a registration of all uses of products that are
known to be carcinogenic.
Risk Evaluation
The methods for evaluating cancer risks in
human populations from known or potential expo-
sures to carcinogens are still poorly defined and
mostly provide soft evidence. It is therefore essen-
tial that highly qualified professional expertise be
used to define the extent ofarbitrariness and uncer-
tainty inherent in the process. A constant guideline
should be not to underestimate the risk. Critical
issues in risk assessment methodology have been
recently reviewed (21-24). The following aspects
need to be considered.
(1) Sources ofevidence should include extent and
definition of exposure in humans, epidemiologic
evidence ofrisk, and experimental evidence ofrisk.
(2) Analysis of the adequacy and quality of the
evidence should provide a critical assessment of
methodologies including detailed reviews of bioas-
say protocols and results of the extent of
documentation.
on the basis of the limited sensitivity of each of the
methods used (e.g., sample size, extent ofobserva-
tions, extent of controls): this consideration is par-
ticularly important in evaluating apparently nega-
tive results which are always limited by the sensitiv-
ity of the method and therefore by the detectability
of the effect.
(4) Quantitative dose-response extrapolations
should be confined to extrapolations from known
exposure with known responses to much lower
levels of exposure with unknown responses, within
the same biological system. Several mathematical
models have been proposed for this extrapolation
and it is important that they be chosen so that they
would not underestimate the projected risk.
(5) Species conversion factors should be included
in estimating risk levels for one species (e.g., hu-
mans) from data obtained in another species. Many
variables combine in determining such a species
conversion factor, such as body surface, body
weight, metabolic pathways, nutritional conditions,
genetic variability, bacterial flora, tissue distribu-
tion, retention and fate of the chemical, etc. It is
extremely difficult to arrive at precise numerical
values in such a conversion procedure without pre-
cise comparative measurements of specific vari-
ables in the two species, including an estimate of
their interindividual variability. No indication is
presently available ofthe extent of sampling neces-
sary for an adequate evaluation ofa human popula-
tion in this field. For exposures to the general popu-
lation, one should consider all ages, transplacental
exposures, concurrent disease conditions, and spe-
cial susceptibility states. In the absence of precise
objective data, one should clearly state the adopted
limits ofuncertainty and provide for a large margin
oferror in each determination, always on the side of
not underestimating the risk.
(6) Model conversion factors should also be in-
cluded to accountforthe role ofadditional variables
when observations were obtained from exposure
conditions in one species that are markedly differ-
ent from those in the population (e.g., consider dif-
ferent routes or modes ofexposures, vehicles, mod-
ifying factors, variations in age, sex, perinatal ex-
posures, disease states, single versus multiple ex-
posures, etc.) Hard data are rarely available and
prudentjudgment ofthese factors is required.
In conclusion, at the present time there does not
appear to be any reliable method for obtaining a
direct estimate of risk and the required confidence
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sure to a carcinogen, except by direct observations
of exposed populations after the fact. Risk evalua-
tion is of such an elusive nature that the best that
science can do, at the present state of our knowl-
edge, is to attempt to estimate an upper bound of
risk, and even this with all the caveats mentioned
above. I believe that it is essential that all the steps
that have gone into the final estimate of risk, or of
its upper bound, be documented and defined in each
case, so that they can be corrected when new in-
formation becomes available.
Benefits Evaluation
A critical analysis ofthe benefits that may derive
from the production and use ofan agent needs to be
made by experts in all the relevant fields in each
case. Benefits can be of a direct or indirect nature
and they can affect the technology, the economy
and the health of populations and of selected indi-
viduals. They need to be precisely defined and
documented for each of these aspects by appro-
priate and rigorous methods. The adequacy, qual-
ity, and reliability of this documentation must be
assessed. In the evaluation of benefits it is impor-
tant to identify the individuals or groups in a popu-
lation which will receive the projected benefits and
to determine whether they are the same that will be
also affected by the risks.
Analysis of Technological Alternatives
In the evaluation of the balance of benefits and
risks, critical consideration must be given to all the
options presented by technological alternatives,
ranging from adoption of different technologies, to
product replacement and to effective reduction or
elimination ofspecific exposures. Replacement ofa
chemical having a certain estimated carcinogenic
risk with another chemical of unknown risk may
mean the adoption ofa more hazardous alternative:
therefore the adoption ofalternate products or con-
ditions must be carefully evaluated for its total im-
pact on health as well as other societal needs. For
each technological alternative under consideration,
documentation ofall the aspects ofrisk and benefits
evaluations should be obtained and critically re-
viewed.
The estimated least hazardous technological al-
ternative should be identified and the feasibility of
its implementation should be determined, in order
to select the best technology acceptable for im-
plementation by society.
Comparative Judgment and Decision
When objective critical reviews and assessments
have been obtained, separately, on benefits, risks
and technological alternatives, then comparative
judgments and operational decisions have to be
made with a sound understanding of the factors in-
volved and with a far-reaching view of the societal
implications of these decisions in terms of public
policy. This process is really a policy choice.
Consideration should be given to the voluntary or
involuntary nature of the individual exposures and
to the intentional or unintentional nature of human
exposures resulting from the production or use of a
given chemical. The mechanisms by which society
will implement and accept a selected technology
will have to be identified (e.g., legislation, regula-
tion, legal action, education, voluntary action, ad-
vertising, etc.). The responsibilities of society to
the individuals placed at higher risk, particularly if
they are not the recipients of benefits, have to be
considered.
Open Public Documentation
Many selected technologies may retain an inher-
ent level of risk, which should be openly stated.
The entire documentation used in this process
should be made public. The extent of arbitrariness
and uncertainty in this documentation should be
clearly stated and attention should be given to iden-
tifying gaps in our knowledge which, iffilled, could
provide a new basis for decision. Each case should
be reviewed periodically.
In conclusion, having determined social accepta-
bility, the selected technological alternative should
be implemented, the public fully informed, the im-
plementation monitored and its consequences ob-
served. The whole problem of evaluation of en-
vironmental hazards is at the interface of science
and policy. The objectivity ofscientific observation
should be rigorously preserved. Recognition of the
etiological role of an environmental agent for a
disease condition elicits an ethical problem. The re-
lationships ofetiology and ethics were recently dis-
cussed (24).
Animal-to-Human Correlations,
with Special Emphasis on
Respiratory Carcinogenesis
We do not presently have any reliable method for
a direct quantitative extrapolation from animal ex-
periments to human carcinogenic hazards.
Mathematical approaches alone are inadequate to
Environmental Health Perspectivescope with the problem, but they suggest that any
amount of carcinogen, however small, will contrib-
ute to the total carcinogenic effect in the population
by raising, however slightly, the level ofresponse of
the total population (6, 21, 23).
The problem of animal-to-human correlations, in
my view, is centered on bridging the gap between
whole-animal experiments and human pathology by
devising a step-by-step analysis ofthe biological re-
sponse under gradually different but closely com-
parable conditions. These comparative studies
begin with the development of whole-animal mod-
els, continue with studies on the response of
specific animal tissues, then extend to in vitro
systems for the same animal tissues and cells in
culture, and finally reach the study of the corre-
sponding human tissues and cells in culture and
their correlation to human pathology in vivo.
Our laboratories have developed this approach,
with particular emphasis on respiratory tract car-
cinogenesis studies. The sequence of research
methods developed in this area is now being ex-
tended also to other tissues and organs (2, 6, 25).
We first developed methods for the induction of
respiratory tract cancers in animals, including
bronchogenic, tracheal, and laryngeal carcinomas,
closely resembling their human counterpart. Their
induction was obtained by exposure to polycyclic
hydrocarbon carcinogens carried by particulate
materials. Morphological characterization, dose-
response relationships, the role of particulate car-
riers and susceptibility factors were defined in this
model (26-34).
This model has been largely used in a series of
subsequent studies by several investigators. Similar
methods were developed in other laboratories
(35-37). Systemically acting respiratory carci-
nogens were also identified (38-41). Synergistic
effects between topical and systemic carcinogens
were observed (30, 40, 42). Histogenesis studies, at
the optical and electron-microscopic level, defined
the early stages of tissue response (43-48).
Methods were then developed for the analysis of
cellular structures and of morphological-biochem-
ical correlations in the response oftarget epithelia to
carcinogens in vivo orin organ culture (49-53). Cellu-
lar control mechanisms, capable of inhibiting the
carcinogenic effect, were identified and studied; this
approach, both at the cellular and at the whole ani-
mal levels, brought on the discovery of the anticar-
cinogenic activity of vitamin A and derivatives (ret-
inoids) including a number of synthetic products of
high biological activity (27, 45, 51, 54-58).
Finally in the lastfew years, the development ofin
vitro culture methods for human tissues has made it
possible to extend the focus of these studies to the
direct observation of the effects of carcinogens in
human target tissues, under controlled experimental
conditions in organ and cell culture.
Human bronchial epithelium, maintained in cul-
ture for as long as six months, has been used in a
variety of short-term and long-term studies in our
laboratory (59-63). From this work a pattern of re-
sponse ofthe human target tissue to respiratory car-
cinogens is emerging, showing a high degree of indi-
vidual variability in the level ofcarcinogen bound to
DNA in human bronchial epithelia but showing a
basic similarity of the pathways of metabolic activa-
tion of carcinogens between animal and human tis-
sues. The specific principal adduct formed in the
binding of benzo[a]pyrene to DNA has been iden-
tified in animal and human bronchial cells (64).
The characteristics ofindividual susceptibility and
the effects of different carcinogens directly on
human respiratory tissues are thus in the process of
being identified and quantitatively defined.
The development of these new research methods
is expected to provide an entirely new, experimen-
tally controlled and quantifiable approach to the old
problem of how to correlate animal and human ob-
servations in carcinogenesis (2).
The section of this paper on "Evaluation of Risks" was pre-
sented in part at the 11th Canadian Cancer Research Conference,
Toronto, 1976.
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